JFK Communications has been the PR agency of record for Prometheus Labs and its lead oncology product, Proleukin® (aldesleukin) since 2009. Proleukin (IL-2) is an FDA-approved immunotherapy for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma.

Throughout our partnership, JFK Communications leads patient advocacy and physician programs designed to engage both audiences regarding treatment options and the potential long-term benefits of Proleukin therapy. In this capacity, JFK Communications provides:

Patient Education Workshops/Special Events
Patient Advocacy Relations
Patient Relations and Education
Speaker Training and Compliance
Professional/Physician Communications
Review and Bylined Articles
Press Release Development
Trade Media Relations
Medical Congress Support
Data Communications
Advertorial Supplements
Web and Digital Media Support

Reach Out

Ready to tell your story ?